Drug Trial Radar · NCT03710915
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Oct 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Jan 12, 2019
Primary completion
Sep 28, 2022
Study completion Jun 28, 2023
Sponsor
- Lead sponsor
- HitGen Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.
Conditions
- Multiple Myeloma
- Relapsed and Refractory Multiple Myeloma
Interventions
HG146Drug
HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose of HG146Time frame: Up to 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HitGen Inc
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.